logo
  • Über uns
    • Über uns
    • Führungsteam
    • Partnerschaften
  • Technologie
    • Technologie
    • Produktion
    • Publikationen
  • Pipeline
  • Newsroom
    • News
    • Events
    • Downloads
  • Investor Relations
    • Überblick
    • Aktieninformation
    • Analysten-Coverage
    • Hauptversammlung 2022
    • Finanzberichte
    • Corporate Governance
    • E-Mail Alert
  • Karriere
    • Werden Sie Teil der RNA people
    • Ausbildung
    • Aktuelle Stellenangebote
  • DE

Clinical Data

Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine


by Bettina Joedicke-Braas

Intratumoral RNA-based TLR-7/-8 and RIG-I Agonist CV8102 alone and in combination with anti-PD-1 in a phase I dose-escalation and expansion trial in patients with advanced solid tumors


by Sovereign

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial


by Sovereign

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer


by Sovereign

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer


by Sovereign

Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist in patients with advanced solid tumors


by Sovereign

Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial


by Sovereign

Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy


by Sovereign

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity


by Sovereign

Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study


by Sovereign

  • 1
  • 2
CureVac N.V.
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac AG
Standort Tübingen, DeutschlandHauptsitzFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac AG
Standort Frankfurt, DeutschlandKlinische EntwicklungSchumannstr. 2760325 FrankfurtT +49 69 7680 587 - 0F +49 69 7680 587 - 2222
CureVac Real Estate GmbH
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Corporate Services GmbH
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Inc.
Standort Boston, USA250 Summer St 3rd FlBoston, MA 02210, USAP +1 617 377404 - 0
CureVac Swiss AG
Standort Basel, SchweizWartenbergstraße 40CH-4052 BaselT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac RNA Printer GmbH
Standort Tübingen, DeutschlandFriedrich-Miescher-Str. 1572076 TübingenT +49 7071 9883 - 0F +49 7071 9883 - 1101
CureVac Belgium SA
Standort Ottignies-Louvain-la-Neuve, BelgienAv. Jean Monnet 41348 Ottignies-Louvain-la-Neuve
Social

© 2022 CureVac AG

KontaktImpressumDatenschutzerklärungAllgemeine Geschäftsbedingungen